NASDAQ$COLL
Collegium Pharmaceutical Inc · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Collegium reported record quarterly revenue and net income in the first quarter of 2021.
Collegium Pharmaceutical, Inc. reported record quarterly net revenue of $87.7 million and net income of $15.7 million for the first quarter ended March 31, 2021. The company experienced growth in Xtampza ER and Nucynta franchise revenues, and raised its Nucynta franchise and adjusted EBITDA 2021 guidance range.
- Record quarterly net revenue achieved, driven by Xtampza ER and Nucynta franchise.
- Xtampza ER market share grew to 30.6% in March 2021.
- Colleen Tupper appointed as the Company’s next CFO, effective May 24, 2021.
- Nucynta franchise and Adjusted EBITDA 2021 guidance range raised.
Headline financials
Revenue & EPS history
Collegium · Revenue · Quarterly
$87.7M
Revenue by segment
Collegium · $87.7M total across 2 segments · Q1 2021
- Nucynta Franchise$52.3M+16.2%59.6%
- Xtampza ER$35.4M+12.4%40.4%
Forward guidance
The Company updates its full-year 2021 financial guidance for Nucynta Franchise Revenues and Adjusted EBITDA.
Tailwinds
- Xtampza ER Revenues guidance unchanged at $155.0 to $165.0 million.
- Nucynta Franchise Revenues guidance raised from $175.0 to $185.0 million to $185.0 to $195.0 million.
- Total Operating Expenses guidance unchanged at $125.0 to $135.0 million.
- Adjusted EBITDA guidance raised from $160.0 to $170.0 million to $170.0 to $180.0 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2021
+2.6%
Avg return
Earnings day
+4.9%
Avg return
5 days after
+2.2%
Avg return
30 days after
61%
28 / 46 earnings
Positive
+31.2%
Q3 2019
Best reaction
-17.6%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +7.7% | -2.2% | -8.9% | |
| Q4 2025 | -3.5% | -12.6% | -29.1% | |
| Q3 2025 | +4.4% | +16.5% | +17.8% | |
| Q1 2025 | +5.9% | +6.6% | +10.7% | |
| Q4 2024 | +2.2% | +0.2% | +4.5% | |
| Q3 2024 | -6.8% | -9.0% | -13.1% | |
| Q2 2024 | +2.5% | +5.9% | +7.3% | |
| Q1 2024 | -17.2% | -12.5% | -12.8% | |
| Q4 2023 | +14.5% | +15.8% | +25.1% | |
| Q3 2023 | +4.6% | +10.8% | +23.0% | |
| Q2 2023 | +6.8% | +9.5% | +7.9% | |
| Q1 2023 | +3.6% | +6.4% | -2.2% | |
| Q4 2022 | +1.7% | +0.5% | -10.0% | |
| Q3 2022 | +6.9% | +11.9% | +30.6% | |
| Q2 2022 | +11.4% | +7.2% | -1.0% | |
| Q1 2022 | +1.7% | +10.0% | +15.9% | |
| Q4 2021 | -14.0% | -17.7% | -14.1% | |
| Q3 2021 | -5.3% | +1.0% | -12.5% | |
| Q2 2021 | -17.6% | -23.7% | -19.2% | |
| Q1 2021 | +3.6% | -0.3% | -1.8% | |
| Q4 2020 | -9.6% | -14.1% | -8.8% | |
| Q3 2020 | +2.2% | +4.3% | +1.9% | |
| Q2 2020 | +6.6% | +13.4% | +16.4% | |
| Q1 2020 | +9.4% | +16.2% | +0.3% | |
| Q4 2019 | +5.2% | -1.5% | -27.4% | |
| Q3 2019 | +31.2% | +38.5% | +53.5% | |
| Q2 2019 | +4.0% | +9.6% | +0.9% | |
| Q1 2019 | +5.6% | -2.9% | -18.0% | |
| Q4 2018 | +18.5% | +22.4% | +2.0% | |
| Q3 2018 | -0.4% | +10.8% | +23.1% | |
| Q2 2018 | -5.7% | -2.0% | -15.7% | |
| Q1 2018 | +11.6% | +8.6% | +9.7% | |
| Q4 2017 | +17.9% | +6.3% | -11.9% | |
| Q3 2017 | +25.8% | +44.7% | +75.2% | |
| Q2 2017 | -4.2% | -0.1% | -2.4% | |
| Q1 2017 | +12.5% | +11.5% | +28.0% | |
| Q4 2016 | +7.9% | +7.4% | -34.6% | |
| Q3 2016 | +7.9% | +1.8% | -0.1% | |
| Q2 2016 | -13.1% | -9.7% | -23.8% | |
| Q1 2016 | -3.0% | — | — | |
| Q4 2015 | -5.6% | — | — | |
| Q3 2015 | -10.4% | — | — | |
| Q2 2015 | -4.3% | — | — | |
| Q1 2015 | -0.8% | — | — | |
| Q1 2014 | -0.8% | — | — | |
| Q4 2014 | -0.8% | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro